In gene therapy to treat adenosine deaminase deficiency disorder, which of the patients blood cells are used?

Options

A. Thromboecytes
B. Erythrocytes
C. Lymphocytes
D. Both Enrythorocytes and Lymphocytes

Answer

**Step-by-Step Solution:**

1. **Understanding Adenosine Deaminase Deficiency:**
- Adenosine deaminase (ADA) deficiency is a metabolic disorder that leads to severe immunodeficiency. It is an autosomal recessive condition that affects the immune system, making individuals more susceptible to infections.

2. **Identifying the Affected Cells:**
- In ADA deficiency, the primary cells affected are lymphocytes, which are a type of white blood cell crucial for the immune response. These cells are responsible for fighting infections.

3. **Gene Therapy Approach:**
- In gene therapy for ADA deficiency, the patient's lymphocytes are collected. This is done to introduce a functional copy of the ADA gene into these cells, which can help restore their function and improve the patient's immune system.

4. **Reintroduction of Modified Cells:**
- After modifying the lymphocytes (usually through a viral vector that carries the ADA gene), these cells are then reintroduced into the patient's body. This process helps to increase the number of functional lymphocytes, thereby improving the patient's immunity.

5. **Conclusion:**
- Therefore, the blood cells used in gene therapy to treat adenosine deaminase deficiency disorder are lymphocytes.

**Final Answer: Lymphocytes.**

---